Tumor‐Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells
Advanced Science · 2026
DOI: 10.1002/advs.202509074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Hui Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of D…. Hauptthemen laut MEDLINE: Pancreatic Stellate Cells, Tumor Microenvironment, Pancreatic Neoplasms, Interleukins. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Municipal Education Commission Research Program Project, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Severe fibrosis, predominantly driven by the activation of pancreatic stellate cells (PSCs), plays a crucial role in the poor prognosis associated with pancreatic ductal adenocarcinoma (PDAC). Understanding the intricate interplay between tumor cells and their microenvironment is essential for deciphering the regulatory mechanisms underlying PSC activation. This study sheds light on the critical role of tumor‐derived interleukin‐35 (IL‐35) in modulating PSC activation, thereby unveiling a promising therapeutic target for mitigating PDAC progression. This study demonstrates that IL‐35, secreted by PDAC cells, serves as a key mediator of bidirectional communication between PDAC cells and PSCs, exacerbating fibrosis. Specifically, IL‐35 upregulates the expression of IGFBP2 and Tsp‐1 in PDAC cells, which subsequently activates PSCs through the IGF‐1R/phosphoinositide 3‐kinase/Akt and transforming growth factor beta signaling pathways, respectively. This sequential activation fosters an environment conducive to tumor cell proliferation and migration, ultimately driving accelerated tumor growth. Collectively, these findings indicate that IL‐35 is a promising therapeutic target whose blockade not only suppresses PSC activation and stromal fibrosis, but also enhances the efficacy of standard chemotherapies (gemcitabine and gemcitabine/nab‐paclitaxel). This provides a strong rationale for its clinical development as a combinatorial strategy in PDAC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Draggability Evaluation and Systematic Translational Medicine, Tianjin…
- Department of Anesthesia, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, P. R. China.
- Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, P. R. China.
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China.
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, 100142, P. R. China.
- National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Cancer Hospital Airport Hospital, Tianjin, 300000, P. R. China.
ORCID-Profile: Chongbiao Huang
Förderung
- Tianjin Municipal Education Commission Research Program Project
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Natural Science Foundation of Tianjin
- Tianjin Key Medical Discipline (Specialty) Construction Project
- Natural Science Foundation of Tianjin Municipality
Zitieren
APA
Li, H., Sun, H., Liu, J., Wu, Y., Wei, L., Li, J., Yuan, Y., Xie, P., Xu, C., Luo, G., Guan, Y., Feng, Y., Chang, A., Hao, J., & Huang, C. (2026). Tumor‐Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells. Advanced Science. https://doi.org/10.1002/advs.202509074
Vancouver
Li H, Sun H, Liu J, Wu Y, Wei L, Li J, et al. Tumor‐Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells. Advanced Science. 2026. doi:10.1002/advs.202509074
BibTeX
@article{Li2026,
author = {Li, Hui and Sun, Huizhi and Liu, Jing and Wu, Yan and Wei, Lin and Li, Jianming and Yuan, Yudong and Xie, Peng and Xu, Chao and Luo, Guolu and Guan, Yuqi and Feng, Yukuan and Chang, Antao and Hao, Jihui and Huang, Chongbiao},
title = {Tumor‐Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202509074}
}
EUVIMED